Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Zrifin, Israel Clinical Trials

A listing of Zrifin, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (30) clinical trials

Early Movements as a Predictor of Future Developmental Delay

Cerebral Palsy (CP) is a motor development problem with a prevalence of 2 per 1000 live birth. There are many etiologies to the syndrome such as: brain malformations, infections during pregnancy, pre and perinatal, anoxic brain damage etc. A high risk group for these causes is preterm infants and infants ...

Phase

8.73 miles

Learn More »

Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy

This is a phase I single-center study of fecal microbiota transplant (FMT) in melanoma patients who failed at least one line of PD-1 blockade. Eligible patients must have a disease amenable to biopsy and lack of contra-indications to FMT. Patients will undergo a baseline evaluation including imaging, tumor biopsy, blood ...

Phase

8.73 miles

Learn More »

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

The purpose of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL).

Phase

8.73 miles

Learn More »

Ilaris (Canakinumab) in Patient With Periodic Fever Aphthous Stomatitis Pharyngitis and Cervical Adenitis (PFAPA)

Study Objectives: Primary objective: Patients will experience at least 50% reduction in PFAPA flares for the next 2 consecutive months after receiving single dose of canakinumab (4 mg/kg). Secondary objectives: Time to flare Parent/patient quality of life assessment Study rationale: Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis (PFAPA) is ...

Phase

9.18 miles

Learn More »

Evaluation of Pain Reduction in the Administration of Saline Injections by the Usage of Pneumatic Skin Flattening

Injections are currently the gold-standard for administrating various medications parenterally. The most significant side-effect related to injections is the accompanying pain. Injection pain is related to the penetration of the skin by the needle and to the mechanical and chemical effects of the drug during and after its injection. This ...

Phase

9.49 miles

Learn More »

ACPs Combined With CABG in Patients With CHF

Five CAD patients who required CABG with or without congestive heart failure will undergo screening and receiving of ACPs 's injection by direct intramuscular during CABG operation. After that,the patients will come to follow up with investigator at 1 and 3 months post surgery in order to evaluate safety and ...

Phase

9.49 miles

Learn More »

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

This multicentre, open-label, dose escalating, Phase I study will enrol approximately 18 patients with progressive and/or multiple recurrent GBM, who after failure of standard therapies will receive GMP Human- recombinant Bone Morphogenetic Protein 4 via intra-tumour and interstitial delivery by CED. Patients will undergo a resection or biopsy of the ...

Phase

9.49 miles

Learn More »

A Study of PDR001 in Combination With CJM112 EGF816 Ilaris (Canakinumab) or Mekinist (Trametinib)

The purpose of this study is to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Phase

9.49 miles

Learn More »

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC. During the dose-escalation part of each treatment arm, patients will be treated with fixed doses ...

Phase

9.49 miles

Learn More »

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

This study will determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose of MK-4830 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advance solid tumors.

Phase

9.49 miles

Learn More »